Project Grant R01CA305895
Award Date 7/3/26
Completion Date 6/30/31
Dollars Obligated $635K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $113,766 Project Grant to the University of Wisconsin–Madison, effective January 12, 2026 through July 16, 2028, under the Cancer Research Manpower program (CFDA 93.398). This award supports research combining antigen-specific cancer vaccination with radiopharmaceutical therapy (RPT) to enhance anti-tumor immunity in metastatic castration-resistant prostate cancer. The project investigates the synergistic effects...
- Federal Project Grant Award Summary The University of Wisconsin-Madison received a $630,171 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 12, 2025, with a completion date of July 31, 2030. The award supports the development of targeted radiopharmaceutical therapies (RPTs) for triple-negative breast cancer (TNBC), an aggressive breast cancer subtype that lacks expression of estrogen receptor, progesterone...
- Federal Grant Award Summary The University of Wisconsin-Madison received a $2.58 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), awarded August 11, 2025, and extending through July 31, 2030. This multi-institutional research program investigates the molecular drivers and therapeutic susceptibilities in lineage state transitions of metastatic castrate-resistant prostate cancer (MCRPC). The project addresses critical...
- Federal Project Grant Award Summary The University of Wisconsin–Madison received a $508,651 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded June 2, 2026, with a completion date of May 31, 2031. This research initiative will deliver fundamental cancer biology research focused on understanding and therapeutically exploiting the role of the neuropeptide receptor PAC1 (pituitary adenylate cyclase-activating polypeptide...
- Summary of Federal Project Grant Award The University of Wisconsin System has received a $1.84 million project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), awarded September 1, 2025, with a completion date of August 31, 2028. This award funds research and development of shark antibody radiopharmaceuticals for the treatment of prostate cancer. The research will be conducted at the University of Wisconsin-Madison campus in Madison,...
- Federal Project Grant Award Summary The University of Wisconsin-Madison received a $603,981 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded August 18, 2025, with completion targeted for July 31, 2030. This research initiative develops and validates integrated clinical-grade artificial intelligence (AI) biomarkers combining genomic and digital pathology analysis to improve risk stratification and treatment...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $585,625 Project Grant to the University of Wisconsin–Madison under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. This five-year research initiative focuses on defining and exploiting the role of the nociceptor neuron-tumor-pericyte axis that drives melanoma progression via Calcitonin Gene-Related Peptide (CGRP)–Receptor Activity-Modifying Protein 1 (RAMP1) signaling....
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $575,178 Project Grant to the University of California, San Francisco on May 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The research project, extending through April 30, 2031, focuses on developing a novel class of radiopharmaceuticals called "Restricted Interaction Peptides" (RIPs) for targeted radiotherapy (TRT) and molecular imaging of prostate cancer. The work...
- Federal Project Grant Award Summary The University of Washington Office of Sponsored Programs received a $686,271 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded May 1, 2026, with completion targeted for April 30, 2031. The grant funds development of proteomics-driven analysis and robotics-enabled drug testing methodologies for microdissected tumors and their microenvironments. The research leverages the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of California, Los Angeles a $404,972 Project Grant effective August 1, 2025, through July 31, 2027, under the Cancer Treatment Research program (CFDA 93.395). This award supports fundamental and applied research investigating mechanisms of radiopharmaceutical therapy (RPT) resistance in metastatic castration-resistant prostate cancer. The research will evaluate how the ectonucleotidase enzyme ENPP1...